Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.
Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature.
复制标题
DOI：
10.2147/tcrm.s55313
复制
发表时间：
2015
影响因子：
2.8
通讯作者：
Bobo WV
中科院分区：
文献类型：
--
作者：
Kelliny M;Croarkin PE;Moore KM;Bobo WV
沃替西汀是最近在美国被批准用于治疗成人重度抑郁症（MDD）的抗抑郁药物之一，本文综述了沃替西汀的药理学概况、现有疗效和耐受性/安全性数据。沃替西汀治疗成人重度抑郁症的疗效得到了8项短期阳性（6- 12周）随机、安慰剂对照试验和1项随机、双盲、52周复发预防试验的支持。根据短期随机试验和长期研究的汇总数据，vortioxetine似乎具有良好的耐受性，并且对性功能的不良影响发生率低。沃替西汀似乎也能有效治疗老年人重度抑郁症的症状，这是基于一项针对这一特定人群的随机试验的结果。然而，缺乏直接比较vortioxetine与其他已建立的抗抑郁药物的临床效果的有效性研究，目前还没有证据表明vortioxetine比其他类型的抗抑郁药物更有效。对沃替西汀在成人重度抑郁症的广泛药物治疗中的地位提出了一些初步建议。
This article reviews the pharmacological profile and available efficacy and tolerability/safety data for vortioxetine, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vortioxetine for treating MDD in adults is supported by eight positive short-term (6- to 12-weeks) randomized, placebo-controlled trials, and one positive randomized, double-blind, 52-week relapse prevention trial. Based on pooled data from short-term randomized trials and from longer-term studies, vortioxetine appears to be well tolerated and to have a low incidence of adverse effects on sexual functioning. Vortioxetine also appears to be effective for treating symptoms of MDD in the elderly based on the results of one randomized trial for which recruitment was focused on this specific population. Nevertheless, effectiveness studies that directly compare the clinical effects of vortioxetine with other established antidepressant drugs are lacking, and there is no evidence as yet that vortioxetine is more clinically effective than other types of antidepressants. Some preliminary suggestions concerning the place of vortioxetine among the broad range of pharmacological treatments for adults with MDD are provided.